Wells Fargo & Company MN Has $132,000 Stock Holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Wells Fargo & Company MN lifted its holdings in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 51.7% in the fourth quarter, Holdings Channel.com reports. The fund owned 9,493 shares of the company’s stock after purchasing an additional 3,236 shares during the quarter. Wells Fargo & Company MN’s holdings in Tyra Biosciences were worth $132,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of TYRA. Barclays PLC grew its stake in Tyra Biosciences by 200.5% during the third quarter. Barclays PLC now owns 37,625 shares of the company’s stock worth $884,000 after buying an additional 25,106 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Tyra Biosciences by 1.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock worth $8,667,000 after purchasing an additional 3,896 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Tyra Biosciences in the fourth quarter valued at approximately $149,000. Rhumbline Advisers lifted its stake in shares of Tyra Biosciences by 4.1% in the 4th quarter. Rhumbline Advisers now owns 26,202 shares of the company’s stock valued at $364,000 after purchasing an additional 1,027 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of Tyra Biosciences by 5.2% in the 4th quarter. Bank of New York Mellon Corp now owns 45,007 shares of the company’s stock valued at $626,000 after acquiring an additional 2,221 shares during the last quarter. Institutional investors own 84.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TYRA. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Friday, March 28th. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research report on Monday, March 31st. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $30.83.

Tyra Biosciences Stock Up 0.2 %

Tyra Biosciences stock opened at $10.09 on Friday. Tyra Biosciences, Inc. has a 12-month low of $6.42 and a 12-month high of $29.60. The company has a market capitalization of $535.68 million, a PE ratio of -6.27 and a beta of 1.17. The firm’s fifty day moving average is $9.64 and its 200 day moving average is $13.21.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. Sell-side analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.